All In Biotech

Drug Trial Radar · NCT07005180

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Dec 31, 2026

Study completion Mar 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
The Parkinson Study Group; Massachusetts General Hospital (PI: Michael Schwarzschild MD,PhD, Co-PI: Stephen Gomperts MD,PhD); Michael J. Fox Foundation for Parkinson's Research
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

Conditions

  • Parkinson Disease

Interventions

  • HBI-002Drug

    Oral liquid containing carbon monoxide

  • Vehicle (placebo)Drug

    Vehicle control (placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of treatment-emergent AEs related to HBI-002 compared to placebo.Time frame: From treatment to 30 days after the end of treatment

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • The Parkinson's & Movement Disorder Institute

    Fountain Valley, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

  • University of Michigan

    Ann Arbor, Michigan · Not yet recruiting

  • Michigan State University

    East Lansing, Michigan · Not yet recruiting

  • Quest Research Institute

    Farmington Hills, Michigan · Recruiting

  • Weill Cornell Medical College

    New York, New York · Recruiting

  • Inland Northwest Research

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.